Frankfurt - Delayed Quote EUR

SELLAS Life Sciences Group, Inc. (RXK3.F)

1.1760

+0.0960

+(8.89%)

At close: April 23 at 3:28:04 PM GMT+2

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

- ASCO Presentation to Highlight Preclinical Efficacy of SLS009 (tambiciclib) in ASXL1 Mutated Colorectal Cancer -NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 America

GlobeNewswire 14 hours ago

SLS
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - - Overall Response Rate (ORR) of 67% Achieved in Patients with AML-MRC (Target Patient Population of SLS009 in r/r AML) – Exceeding Targeted 20% ORR - - Trial Continues with Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – NEW YORK, April 08, 2025 (G

GlobeNewswire 15 days ago

SLS
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – – Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009 (Tambiciclib) in r/r AML – Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – – Raised $25 Million in Gross Proceeds in a Registered Direct Offering in

GlobeNewswire last month

SLS
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

Funded and conducted by GenFleet Therapeutics, the trial assessed the combination of SLS009 plus Brukinsa.

Clinical Trials Arena last month

SLS
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall Survival Not Reached Yet – 67% of Patients Still Alive - NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer

GlobeNewswire 2 months ago

SLS
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 19,685,040 shares of its common stock (or common stock equivalents in lieu thereof) and

GlobeNewswire 2 months ago

SLS
SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued

SELLAS Life Sciences Group (SLS) shares fell 14% in recent Thursday trading after the company announ

PREMIUM
MT Newswires 2 months ago

SLS
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification – - Based on a Review of Unblinded Data, the IDMC Confirmed that GPS Exceeded the Predetermined Futility Criteria, Noted no Safety Concerns and Commended SELLAS for its Operational Excellence and Study Data Integrity - - Fewer than 50% of Enrolled Patients Confirmed Deceased A

GlobeNewswire 2 months ago

SLS
SELLAS Announces Key Business Objectives for 2025

- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 - - Approval of “tambiciclib” as Recommended International Nonproprietary Name for SLS009 - - Applied for Non-Dilutive Grant Funding to Expand SLS009 Development Into Frontline Setting in AML - - Developing SLS009 Pediatric Programs in Hematological and Potentially Other Malignancie

GlobeNewswire 3 months ago

SLS
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update call on Wednesday, January 8, 2025, at 9:00 a.m. Eastern Time. Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will discuss the Company’s outlook for 2025 and

GlobeNewswire 3 months ago

SLS
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company to Host Webcast Call Today at 9:00 am ET NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today

GlobeNewswire 4 months ago

SLS
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens - - Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML MRC) Prospectively Enrolled in Two Expansion Cohorts; Exceeding Prespecified Target Response Rate of 33% - NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.

GlobeNewswire 4 months ago

SLS
SELLAS announces data indicating key predictor of response to SLS009 in solid cancers

In CRC with MSI-H, ASXL1 mutations were detected in seven out of 12 (58%) of PDCs.

Clinical Trials Arena 4 months ago

SLS
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell Lung Cancer (NSCLC) in Addition to Hematologic Malignancies - - Existing Clinical Data Demonstrating SLS009 Efficacy in ASXL1 mutated AML and Safety Across Multiple Cancer Types Lay Foundation for Targeted SLS009 Clinical Trial in Selected Sol

GlobeNewswire 4 months ago

SLS
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 5 months ago

SLS
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML After Venetoclax Failure to be Presented at the Upcoming American Society of Hematology (ASH) Annual Meeting in December – – GPS Granted FDA Rare Pediatric Disease Designation (RPDD) for the Treatment of Pediatric AML – NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Scien

GlobeNewswire 5 months ago

SLS
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

- Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure – - 50% Response Rate at the Selected Dose Level of 30 mg Twice a Week (BIW) – - 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Survival (OS) of 5.5 Months vs. <2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg BIW Median OS Not Reached - NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASD

GlobeNewswire 5 months ago

SLS
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

- GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - - RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – - Recent Valuations for PRVs Remain Attractive (~$100 million/each) – NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical c

GlobeNewswire 6 months ago

SLS
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 at 9:00 am EDT. Maxim Healthcare Virtual Sum

GlobeNewswire 6 months ago

SLS
Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

We came across a bullish thesis on Sellas Life Sciences Group Inc (SLS) on ValueInvestorsClub by ContraMundem. In this article we will summarize the bulls’ thesis on SLS. Sellas Life Sciences shares were trading at $1.45 when this thesis was published, vs. closing price of $1.26 on Sep 17. Sellas Life Sciences (SLS) is a […]

Insider Monkey 7 months ago

SLS

Performance Overview

Return	RXK3.F	S&P 500 (^GSPC)
YTD	+28.67%	-8.60%
1-Year	-15.88%	+6.02%
3-Year	-57.58%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SELLAS Life Sciences Group, Inc. (RXK3.F)

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Key Business Objectives for 2025

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

SELLAS announces data indicating key predictor of response to SLS009 in solid cancers

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

Performance Overview